US FDA approves Glaukos' new eye therapy-March 2024-www.financetom.com

US FDA approves Glaukos' new eye therapy

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA approves Glaukos' new eye therapy

Oct 20, 2025 4:30 AM

Oct 20 (Reuters) - The U.S. Food and Drug Administration

has approved a new eye therapy from Glaukos Corp ( GKOS ),

giving patients a less painful and more convenient option to

treat a progressive condition that can severely affect vision,

the company said on Monday.

Previous page： Elon Musk says will resign as Twitter CEO when he finds someone ‘foolish’ enough to take the job Next page： Paras Defence bets on drone demand for next spurt of growth

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Elon Musk says will resign as Twitter CEO when he finds someone ‘foolish’ enough to take the job

Dec 20, 2022

Elon Musk has announced that he will step down as Twitter CEO once he finds another person “foolish” enough to take up the job, he tweeted.

Paras Defence bets on drone demand for next spurt of growth

Dec 20, 2022

Paras Defence and Space Technologies’ Director for Business Development Amit Mahajan said the drones market in India is about to explode and there are huge opportunities in the segment.

Big tech bleeds in 2022 — All eyes on what 2023 holds for IT giants amid recession worries

Dec 22, 2022

What is hurting the IT giants are the rising rates of interest being announced by central banks around the world including the US Federal Reserve and the Reserve Bank of India (RBI), macro economic uncertainties i.e. concerns surrounding an impending recession and global pressures.

China supply chain woes threatens short-term outlook, warns Dixon Technologies

Dec 21, 2022

KRChoksey's Deven Choksey believes that a correction in the stock of Dixon would be a welcome opportunity to add the stock to the portfolio.